Multicenter, Randomized, Placebo-Controlled Phase III Study of Pyridoxalated Hemoglobin Polyoxyethylene in Distributive Shock (PHOENIX)*

@article{Vincent2015MulticenterRP,
  title={Multicenter, Randomized, Placebo-Controlled Phase III Study of Pyridoxalated Hemoglobin Polyoxyethylene in Distributive Shock (PHOENIX)*},
  author={Jean Louis Vincent and Christopher T. Privalle and Mervyn Singer and J. A. Lorente and Erwin Dr Med Boehm and Andreas Meier‐Hellmann and Harald Darius and Ricard Ferrer and Josep Maria Sirvent and Gernot Marx and Joseph Deangelo},
  journal={Critical Care Medicine},
  year={2015},
  volume={43},
  pages={57–64}
}
Objective:To compare the effectiveness and safety of the hemoglobin-based nitric oxide scavenger, pyridoxalated hemoglobin polyoxyethylene, against placebo in patients with vasopressor-dependent distributive shock. Design:Multicenter, randomized, placebo-controlled, open-label study. Setting:Sixty-one participating ICUs in six European countries (Austria, Belgium, Germany, the Netherlands, Spain, and United Kingdom). Patients:All patients admitted with distributive shock, defined as the… Expand
A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin(R)) as a resuscitative agent in hypovolemic shock patients
TLDR
Centhaquine treatment significantly reduced 28-day all-cause mortality and is a highly efficacious resuscitative agent for the treatment of hypovolemic shock as an adjuvant to standard of care (SOC). Expand
A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients
TLDR
Centhaquine is an efficacious resuscitative agent for treating hypovolemic shock, and an 8.8% absolute reduction in 28-day all-cause mortality was observed in the centhaqine group. Expand
Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial
TLDR
Improvements in base deficit, multiple organ dysfunction syndrome (MODS) score and adult respiratory distress syndrome (ARDS) were greater in the centhaquine group than in the control group, which improves the clinical outcome of patients with hypovolemic shock. Expand
Antioxidant reserve of the lungs and ventilator‐associated pneumonia: A clinical trial of high dose selenium in critically ill patients
TLDR
Despite increasing the antioxidant activity, selenium supplementation did not affect the incidence of VAP in critically ill patients, and the risk of developing VAP or death within 30 days of ICU admission remained the same in the treatment and the controls. Expand
Vasopressor-Sparing Strategies in Patients with Shock: A Scoping-Review and an Evidence-Based Strategy Proposition
  • P. Guinot, Audrey Martin, +5 authors Maxime Nguyen
  • Medicine
  • Journal of clinical medicine
  • 2021
TLDR
It is demonstrated that several pharmacological and non-pharmacological strategies are associated with a decrease in the duration of vasopressor therapy, and an evidence-based vasopression management strategy is proposed. Expand
Sadly, pyridoxalated hemoglobin polyoxyethylene is more a dodo than a PHOENIX.
  • J. Ball
  • Medicine
  • Critical care medicine
  • 2015
TLDR
The results of the multicenter, randomized, placebo-controlled phase III Study of pyridoxalated hemoglobin polyoxyeth­ ylene (PHP) in patients with vasopressor resistant IDS, the PHEONIX trial are reported. Expand
Resuscitation with pegylated-carboxyhemoglobin preserves renal cortical oxygenation and improves skeletal muscle microcirculatory flow during endotoxemia.
PEGylated-carboxyhemoglobin (PEGHbCO), which has carbon monoxide-releasing properties, plasma expansion and oxygen-carrying properties, may improve both skeletal microcirculatory flow and renalExpand
Red blood cell storage duration and trauma.
  • R. Sparrow
  • Medicine
  • Transfusion medicine reviews
  • 2015
TLDR
Findings from several recent nonrandomized studies examining RBC storage duration and clinical outcomes in trauma patients are reviewed and the rationale for further research on RBCstorage duration in the trauma setting is provided. Expand
Rationale of Hemoadsorption during Extracorporeal Membrane Oxygenation Support
TLDR
A new polystyrene-based device for hemoadsorption, which aims to reduce excessive levels of inflammatory molecules such as interleukins, cytokines as well as damage- and pathogen-associated molecular patterns, has become available. Expand
Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum
TLDR
This review explores the schizophrenic ‘Jekyll-and-Hyde’ characteristics of catecholamines in critical illness, as they are both necessary for survival yet detrimental in excess. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 33 REFERENCES
Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock*
TLDR
PHP is a hemodynamically active nitric oxide scavenger in patients with distributive shock and the role of PHP in distributiveshock remains to be determined. Expand
Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial
TLDR
A supplementary AVP infusion of 0.067 IU/min restores cardiovascular function in patients with advanced vasodilatory shock more effectively than AVP at 0.033  IU/min. Expand
Arginine Vasopressin in Advanced Vasodilatory Shock: A Prospective, Randomized, Controlled Study
TLDR
The combined infusion of AVP and NE proved to be superior to infusion of NE alone in the treatment of cardiocirculatory failure in catecholamine-resistant vasodilatory shock. Expand
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*
TLDR
The causes of death in the study were consistent with those expected in patients with septic shock, although there was a higher proportion of cardiovascular deaths and a lower incidence of deaths caused by multiple organ failure in the 546C88 group. Expand
Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial.
TLDR
Although further analysis should investigate whether the mortality difference was solely due to a direct treatment effect or to other factors, DCLHb does not appear to be an effective resuscitation fluid. Expand
Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-
TLDR
Treatment with the nitric oxide synthase inhibitor 546C88 promoted the resolution of shock in patients with severe sepsis and was associated with an acceptable overall safety profile. Expand
Cardiovascular response to dopamine and early prediction of outcome in septic shock: A prospective multiple-center study*
TLDR
Dopamine sensitivity is associated with decreased mortality rate and early recognition of dopamine resistant septic shock could allow for better screening of patients with an ominous prognosis. Expand
Vasopressin versus norepinephrine infusion in patients with septic shock.
TLDR
Low-dose vasopressin did not reduce mortality rates as compared with norepinephrine among patients with septic shock who were being treated with conventional (catecholamine) vasopressesors, and a test for heterogeneity between these two study strata was not significant. Expand
Arginine vasopressin in 316 patients with advanced vasodilatory shock*
TLDR
Supplementary AVP infusion improved cardiocirculatory function in advanced vasodilatory shock, but an increase in liver enzymes and bilirubin, and a decrease in platelet count occurred during AVP therapy, particularly during simultaneous hemofiltration. Expand
Survival after shock requiring high-dose vasopressor therapy.
TLDR
One in six patients with shock survived to 90 days after HDV; the majority of nonsurvivors died after withdrawal or withholding of life support therapy; stress-dose corticosteroid therapy appears reasonable in patients withshock requiring HDV. Expand
...
1
2
3
4
...